Background
Methods
Study population
Study design
Microbiological methods
Statistical methods
Results
Study population
Variables | Total (n = 221) | Cohort | |||||
---|---|---|---|---|---|---|---|
ST17 (n = 52) | non-ST17 (n = 169) | P value | |||||
Virulence factors | |||||||
esp+hyl+ | 179 (80.9) | 51 (98.1) | 128 (75.7) | < 0.001 | |||
Age/sex/BMI | |||||||
Age (mean ± SD) | 62.3 ± 14.5 | 64.7 ± 14.5 | 61.5 ± 15.0 | 0.752 | |||
Male | 132 (59.7) | 28 (53.8) | 104 (61.5) | 0.323 | |||
BMI ≥ 25 kg/m2 | 48 (21.7) | 10 (19.2) | 38 (22.5) | 0.619 | |||
Underlying condition | |||||||
Decompensated LC | 36 (16.3) | 6 (11.5) | 30 (17.8) | 0.289 | |||
AKI requiring RRT | 58 (26.2) | 10 (19.2) | 48 (28.4) | 0.189 | |||
Diabetes mellitus | 57 (25.8) | 45 (26.6) | 12 (23.1) | 0.609 | |||
Cancer | 67 (30.3) | 18 (34.6) | 49 (29.0) | 0.441 | |||
Hematologic malignancy | 44 (19.9) | 6 (11.5) | 38 (22.5) | 0.084 | |||
Liver transplantation | 15 (6.8) | 0 (0.0) | 15 (8.9) | 0.026 | |||
Neutropenia | 42 (19.0) | 8 (15.4) | 34 (20.1) | 0.447 | |||
CCI (Median, IQR) | 3 (2–5) | 3 (1.25–4) | 3 (2–5) | 0.773 | |||
Invasive procedure/ICU | |||||||
Central venous catheter | 124 (56.1) | 95 (56.2) | 29 (55.8) | 0.955 | |||
Artificial airway | 57 (25.8) | 15 (28.8) | 42 (24.9) | 0.565 | |||
Intra-abdominal surgery | 21 (9.5) | 4 (7.7) | 17 (10.1) | 0.789 | |||
Parenteral nutrition | 114 (51.6) | 25 (48.1) | 89 (52.7) | 0.563 | |||
ICU Stay | 157 (71.0) | 35 (67.3) | 122 (72.2) | 0.497 | |||
Previous antibiotic use | |||||||
Ampicillin | 29 (13.1) | 5 (9.6) | 24 (14.2) | 0.392 | |||
Glycopeptide | 121 (54.8) | 33 (63.5) | 88 (52.1) | 0.149 | |||
3rd- or 4th-generation cephalosporin | 84 (38.0) | 16 (30.8) | 68 (50.2) | 0.219 | |||
Carbapenem | 123 (55.7) | 27 (51.9) | 96 (56.8) | 0.535 | |||
Piperacillin/tazobactam | 132 (59.7) | 29 (55.8) | 103 (60.9) | 0.506 | |||
Metronidazole | 33 (14.9) | 7 (13.5) | 26 (15.4) | 0.734 | |||
Fluoroquinolone | 68 (30.8) | 12 (23.1) | 56 (33.3) | 0.162 | |||
Aminoglycoside | 20 (9.0) | 7 (13.5) | 13 (7.7) | 0.266 | |||
Linezolid | 16 (7.2) | 3 (5.8) | 13 (7.7) | 0.768 |
Patient | Sex | Age | Underlying disease | Neutro-penia | Genotype of rectal isolates | Sequence type of blood isolates | Type of infection | Time interval between rectal carriage and bacteremia (days) | Antibiotic treatment | Outcome of Hospitalization | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vancomycin -resistance gene | Virulence factor | Sequence type | Clonal complex | ||||||||||
A1 | M | 56 | Cancer | − | van A | esp, hyl | 17 | 17 | N/A | Intra-abdominal infection | 139 | Linezolid | Alive |
A2* | F | 52 | Myelodysplastic syndrome | + | van A | esp, hyl | 17 | 17 | 17 | Intra-abdominal infection | 10 | Linezolid Tigecycline | Alive |
A3 | F | 57 | Leukemia | + | van A | esp, hyl | 17 | 17 | N/A | Intra-abdominal infection | 33 | Linezolid | Alive |
A4* | M | 67 | Lymphoma | + | van A | esp, hyl | 17 | 17 | 17 | Intra-abdominal infection | 7 | None | Died of VREF BSI |
A5* | F | 62 | Leukemia | + | van A | esp, hyl | 17 | 17 | 17 | Intra-abdominal infection | 4 | None | Died of VREF BSI |
A6* | M | 70 | Cancer | − | van A | esp, hyl | 17 | 17 | 17 | Intra-abdominal infection | 6 | Linezolid Tigecycline | Died of other cause |
B1* | F | 69 | Liver cirrhosis | − | van A | hyl | 389 | 17 | 389 | Primary bacteremia | 22 | Linezolid | Died of other cause |
B2* | F | 51 | Lymphoma | + | van A | esp, hyl | 981 | 17 | 981 | Urinary tract infection | 12 | Linezolid | Died of other cause |
B3 | M | 78 | Lymphoma | + | van A | esp, hyl | 192 | 17 | N/A | Intra-abdominal infection | 8 | Linezolid | Alive |
B4 | F | 42 | Leukemia | + | van A | esp,hyl | 230 | 17 | N/A | Catheter-related infection | 43 | Linezolid | Died of VREF BSI |
B5* | M | 48 | Leukemia | + | van A | hyl | 252 | 17 | 252 | Catheter-related infection | 3 | Linezolid | Died of other cause |
B6 | M | 54 | Liver transplantation | − | van A | esp, hyl | 978 | 17 | 1421 | Intra-abdominal infection | 162 | Linezolid Tigecycline | Alive |
B7 | F | 58 | Lymphoma | + | van A | esp, hyl | 230 | 17 | 17 | Intra-abdominal infection | 103 | Linezolid | Died of other cause |
B8 | F | 55 | Liver cirrhosis / transplantation | − | van A | esp, hyl | 230 | 17 | 17 | Intra-abdominal infection | 37 | None | Died of other cause |
B9 | M | 56 | Lymphoma | + | van A | esp, hyl | 230 | 17 | 17 | Catheter-related infection | 40 | Linezolid | Died of VREF BSI |
B10 | M | 47 | Liver cirrhosis / Liver transplantation | + | van A | hyl | 1026 | 17 | 981 | Intra-abdominal infection | 187 | Linezolid Tigecycline | Alive |
ST17 as a risk factor for subsequent bacteremia
Variables | Total (n = 221) | Univariate analysis | Multivariable analysis | ||
---|---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | ||
Virulence factors | |||||
Sequence type 17 | 52 (23.5) | 1.78 (0.65–4.91) | 0.264 | 7.14 (1.83–27.83) | 0.005 |
esp+hyl+ | 179 (80.9) | 1.10 (0.31–3.86) | 0.883 | ||
Age/sex/BMI | |||||
Age ≥ 60 years | 132 (59.7) | 0.34 (0.12–0.99) | 0.048* | ||
Male | 132 (59.7) | 0.74 (0.28–1.98) | 0.549 | ||
BMI ≥ 25 kg/m2 | 48 (21.7) | 0.51 (0.12–2.27) | 0.379 | ||
Underlying condition | |||||
Decompensated LC | 36 (16.3) | 1.16 (0.33–4.09) | 0.813 | ||
AKI requiring RRT | 38 (17.2) | 3.07 (1.06–8.92) | 0.039 | ||
Diabetes mellitus | 57 (25.8) | 0.74 (0.21–2.59) | 0.636 | ||
Metastatic cancer | 67 (30.3) | 0.38 (0.09–1.67) | 0.200 | ||
Hematologic malignancy | 44 (19.9) | 10.45 (3.78–29.07) | < 0.001 | 20.97 (5.01–87.82) | < 0.001 |
Liver transplantation | 15 (6.8) | 2.58 (0.73–9.06) | 0.141 | 40.08 (4.87–329.76) | 0.001 |
Neutropenia | 42 (19.0) | 8.86 (3.21–24.42) | < 0.001 | ||
CCI ≥ 3 | 123 (55.7) | 1.25 (0.46–3.37) | 0.660 | ||
Invasive procedure/ICU | |||||
Central venous catheter | 124 (56.1) | 3.04 (0.98–9.43) | 0.055 | ||
Artificial airway | 57 (25.8) | 0.92 (0.33–2.73) | 0.945 | ||
Intra-abdominal surgery | 21 (9.5) | 1.86 (0.53–6.55) | 0.332 | ||
Parenteral nutrition | 114 (51.6) | 1.82 (0.66–5.03) | 0.246 | ||
ICU Stay | 157 (71.0) | 1.59 (0.51–4.95) | 0.424 | ||
Previous antibiotic use | |||||
Ampicillin | 29 (13.1) | 0.31 (0.04–2.38) | 0.261 | ||
Glycopeptide | 121 (54.8) | 6.39 (1.45–28.17) | 0.014 | ||
3rd- or 4th-generation cephalosporin | 84 (38.0) | 1.26 (0.47–3.37) | 0.642 | ||
Carbapenem | 123 (55.7) | 4.35 (1.23–15.36) | 0.022 | ||
Piperacillin/tazobactam | 132 (59.7) | 1.04 (0.36–2.77) | 0.994 | ||
Metronidazole | 33 (14.9) | 2.40 (0.83–6.91) | 0.105 | ||
Fluoroquinolone | 68 (30.8) | 0.48 (0.14–1.69) | 0.221 | ||
Aminoglycoside | 20 (9.0) | 1.19 (0.27–5.25) | 0.816 | ||
Linezolid | 16 (7.2) | 2.61 (0.74–9.17) | 0.134 |